Christopher J. Kirk - 23 Jun 2022 Form 4 Insider Report for Kezar Life Sciences, Inc. (KZR)

Role
President and CSO, Director
Signature
/s/ Marc Belsky, Attorney-in-fact
Issuer symbol
KZR
Transactions as of
23 Jun 2022
Net transactions value
+$29,754
Form type
4
Filing time
27 Jun 2022, 18:30:34 UTC
Previous filing
07 Jan 2022
Next filing
10 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KZR Common Stock Options Exercise $29,754 +33,060 +9.5% $0.9000 381,484 23 Jun 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KZR Employee Stock Option (right to buy) Options Exercise $0 -33,060 -21% $0.000000 123,361 23 Jun 2022 Common Stock 33,060 $0.9000 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Total reflects 1,953, 981, 986, 951 and 944 shares of common stock acquired on May 15, 2020, November 15, 2020, May 15, 2021, November 15, 2021 and May 15, 2022, respectively, through the Company's 2018 Employee Stock Purchase Plan.
F2 Fully vested and exercisable.